Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer
A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response…